Neutropenia
Reference List

1. Balducci, L., Hardy, C.L., & Lyman, G.H. (2001). Hematopoietic growth factors in the older cancer patient. Current Opinion in Hematology, 8, 170-187.
2. Balducci, L., Yates, J., & Senior Adult Care Task Force members of the National Comprehensive Cancer Networks. (2000). General guidelines for the management of older patients with cancer. Oncology, 14(11A), 221-227.
3. Blay, J.Y., Gomez, F., Sebban, C., Bachelot, T., Biron, P., Gugliemi, C., Hagenbeek, A., Somera, R., Chauvin, F., & Phillip, T. (1998). The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Blood, 82(10), 3562-3568.
4. Brown, K.A., Esper, P., Kelleher, L.O., O'Neill, J.E.B., Polovich, M., & White, J.M. (Eds.) (2001). Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. Pittsburgh: Oncology Nursing Society.
5. Camp-Sorrel, D. (2000). Chemotherapy: Toxicity management. In C.H. Yarbro, M.H. Frogge, M. Goodman, & S.L. Groenwald (Eds.), Cancer Nursing: Principles and Practice (5th ed). (pp. 444-486). Boston: Jones and Bartlett.
6. Carter, L.W. (1994). Bacterial translocation: Nursing implications in the care of patients with neutropenia. Oncology Nursing Forum, 21(5), 857-867.
7. Chang, J. (2000). Chemotherapy dose reduction and delay in clinical practice: Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. European Journal of Cancer, 36 (Suppl 1), S11-14.
8. Feld, R. (2000). Multinational cooperation in trials and guidelines dealing with febrile neutropenia. International Journal Antimicrobial Agents, 16(2), 185-187.
9. Freifield, A., Marchigiani, D., Wlash, T., Chanock, S., Lewis, L., Hiemenz, J., Hicks, S., Gill, J.E., Steinberg,S.M., & Pizzo, P.A. (1999). A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. New England Journal of Medicine, 341(5), 305-311.
10. Groot, U., Vellenga, E., & Rutten, F.F.H. (1996). An economic model to assess the savings from a clinical application of haematopoietic growth factors. European Journal of Cancer, 32A(1), 57-62.
11. Hayes, N.A. (2001). Analyzing current practice patterns: lessons from Amgen's project Chemoinsight. Oncology Nursing Forum, 28(2), 11-16.
12. Hughes, W.T., Armstrong, D., Bodey, G.P., Bow, E.J., Brown, A.E., Calandra, T., Feld ,R., Pizzo, P.A., Rolston, K.V.I., Shenep, J.L., Young, L.S. (2002). 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer, Clinical Infectious Diseases, 34, 730-751.
13. Intraguntorncha,i T., Sutheesophon, J., Sutcharitchan,. P, & Swasdikul, D. (2000). A predictive model for life-threatening neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin lymphoma. Leukemia and Lymphoma, 37(3-4), 351-360.
14. Kern, W.V., Cometta, A., deBock, R., Langenaeken, J., Paesmans, M., Gaya, H., Zanetti, G., Calandra, T., Glauser, M.P., Crokaert, F., Klastersky, J., Skoutelis, A., Bassaris, H., Zinner, S.H. Viscoli, C., Engelhard ,D., & Padmos ,A. (1999). Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. New England Journal of Medicine, 341(5),312-318.
15. Lyman, G.H. (2000). A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care. European Journal of Cancer, 36(Suppl.), S15-S21.
16. Lyman, G.H. (2000). A predictive model for neutropenia associated with cancer chemotherapy. Pharmacotherapy, 20(7 Pt 2), 104S-111S.
17. Lyman, G.H., Balducci, L., & Agboola, Y. (2001). Use of colony-stimulating factors in the elderly cancer patient. Oncology Spectrums, 2(6), 414-421.
18. Lyman, G.H., Kuderer, N., Greene, J., & Balducci, L. (1998). The economics of febrile neutropenia: implications for the use of colony-stimulating factors, European Journal of Cancer, 34(12), 1857-1864.
19. Lyman, G.H., Kudere, N.M., Balducci, L. (2002). Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. Current Opinions in Hematology, 9(3), 207-214.
20. Lyman, G.H., Lyman, C.G., Sanderson, R.A., & Balducci, L. (1993). Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. Journal of the National Cancer Institute, 85(6), 488-493.
21. Madsen, K., Roseman, M., Hui, S., & Breitfeld , P.P. (2002). Value of electronic data for model validation and refinement: bacteremia risk in children with fever and neutropenia. Journal of Pediatric Hematology/Oncology, 24(4), 256-262.
22. Ozer, H., Armitage, J., Bennett, C., Crawford, J., Demetri, G., Pizzo, P., Schiffer, C., Smith, T., Somlo, G., Wade, J., Wade, J.L., III, Winn, R., Wozniak, A., & Somerfield, M. for the American Society of Clinical Oncology Growth Factors Expert Panel. (2000). Update of recommendations for the use of hemtopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. Journal of Clinical Oncology, 18(20), 3558-3585.
23. Pizzo, P.A. (1999). Current concepts: Fever in immunocompromised patients. New England Journal of Medicine, 341(12), 893-900.
24. Pizzo, P.A. (1999). Drug therapy: Management of fever in patients with cancer and treatment-induced neutropenia. New England Journal of Medicine, 341(18), 1323-1332.
25. Poe , S.S, Larson E, McGuire, D., & Krumm, S. (1994). A national survey of infection prevention practices on bone marrow transplant units. Oncology Nursing Forum, 21(10), 1687-1694.
26. Roseman, M., Madsen, K., Hui, S., 7 Breitfeld, P.P. (2002). Modeling administrative outcomes in fever and neutropenia: Clinical variables significantly influence length of stay and hospital charges. Journal of Pediatric Hematology/ Oncology, 24(4), 263-268.
27. Rubenstein, E.B., Brown, A.E,, Elting, L., Greene, J.N., Ito, J.I. King, E., Marcucci, G., Miller, C.B., Montoya, J., Noskin, G., Reed, E.C., Rolston, K., Schott, A.F., Talcott, J.A., & Wade, J.C. (2000). NCCN practice guidelines for fever and neutropenia. National Comprehensive Cancer Network Retreived 10/22/02
28. Rusthoven, J., Bramwell, V., Stephenson, B., and the Provincial Systemic Treatment Disease Site Group. (1998, update addendum 2000). Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Cancer Prevention and Control 2(4), 179-190.
29. Smith, L.H., & Besser, S.G. (2000). Dietary restrictions for patients with neutropenia: a survey of institutional practices. Oncology Nurse Forum, 27(3), 515-530.
30. Silber, J.H., Fridman, M., DiPaolo, R.S., Erder, M.H., Pauly, M.V., Fox, K.R. (1998). First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. Journal of Clinical Oncology, 16(7), 2392-2400.
31. Silber, J.M., Fridman, M., Shpilskym A,, Even-Shoshan, O., Smink, D.S., Jayaraman, J. Fox, K.R., & Pauly, M.V. (1998). Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. Journal of Clinical Oncology, 16(7), 2435-2444.
32. The Centers for Disease Control and Prevention. (2000). Guidelines for preventing infections among hematopoietic stem cell recipients: Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. 49: RR-10, (pp. 1-128).
33. Wilson, B.J. (2002). Dietary recommendations for neutropenic patients. Seminars in Oncology Nursing, 18(1), 44-49.
34. Zinner , S.H. (1998). Relevant aspects in the Infectious Diseases Society of America (ISDA) guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. International Journal of Hematology, 68(Supp.l 1), S31-S34.